SRTS SENSUS HEALTHCARE

Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024

Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Participants are encouraged to pre-register for the conference call using this . Upon registration participants will receive a unique dial-in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this , which also can be found in the Investor Relations section of the Company’s website at .

Following the conclusion of the conference call, a telephone replay will be available until December 14, 2024 and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International). At the system prompt, enter the replay code 3932512 followed by the # sign. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.



About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit .

Contact:

Alliance Advisors IR

Kim Sutton Golodetz

212-838-3777

# # #



EN
31/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SENSUS HEALTHCARE

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Resul...

REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more tha...

 PRESS RELEASE

Sensus Healthcare Reports Third Quarter 2024 Financial Results With Re...

Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company spe...

 PRESS RELEASE

Sensus Healthcare to Host Third Quarter 2024 Financial Results and Bus...

Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024 BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a d...

 PRESS RELEASE

Sensus Healthcare Sells SRT System to Providence Swedish Hospital

Sensus Healthcare Sells SRT System to Providence Swedish Hospital Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers BOCA RATON, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has shipped an SRT system to Providence Swedish Hospital in Seattle.  This sale represents the Company’s latest success in generati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch